FridayJun 11, 2021 12:15 pm

Fibromyalgia and the Future of Telehealth

Fibromyalgia is an acute illness that can present as cognitive dysfunction, lack of energy, intense fatigue and abnormal pain among other symptoms. Sometimes, individuals who suffer from this condition may experience flares, when their symptoms get too intense. This makes it harder for them to perform simple tasks, even struggling to make it to doctor’s appointments. However, the coronavirus pandemic and improvements in technology have made it possible for fibromyalgia patients to access telehealth appointments, which allows them to talk with their doctor remotely, either via tablet, phone or computer, while they’re home. Patients can now schedule telehealth appointments with…

Continue Reading

FridayJun 11, 2021 9:00 am

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) to Sponsor Kernel Flow, Ketamine Feasibility Study

Feasibility study is designed to measure ketamine’s psychedelic effect on cerebral cortex hemodynamics Cybin, Kernel working together to leverage proprietary Kernel Flow device for psychedelic-based studies and clinical trials Ketamine is a dissociative injected anesthetic that blocks sensory perception Cybin (NEO: CYBN) (OTCQB: CLXPF) has announced a key step forward in its focus on progressing psychedelic therapeutics. The company will be sponsoring a feasibility study of the Kernel Flow technology; the study is designed to measure ketamine’s psychedelic effect on cerebral cortex hemodynamics (https://ibn.fm/BW1Jn).  “We still have much to learn about what is occurring in the brain during a psychedelic…

Continue Reading

FridayJun 11, 2021 9:00 am

Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) on Course for Private Demonstrations of the i/Blue Imaging System(TM) at the American Urological Association Annual Conference in September

Further refinement of if the i/Blue Imaging System will incorporate changes intended to meet critical verification requirements established through benchmark testing of competitive systems as well as feedback from preliminary meetings with the FDA Bladder cancer is anticipated to cause over 1,000,000 physician consultations per year, resulting in $4 billion in total costs for bladder cancer treatment and management Imagin Medical plans to complete its proprietary i/Blue Imaging System in 2022 The National Cancer Institute (“NCI”) lists urinary bladder cancer as the sixth most prevalent form of cancer in the United States. In 2021, NCI estimates that the total number…

Continue Reading

ThursdayJun 10, 2021 2:30 pm

Advancements in Imaging Techniques Allow Physicians to Better Manage Bladder Cancer

In the past few decades, there has been a considerable decline in the mortality rate related to bladder cancer. This, researchers speculate, may be associated with a reduction in smoking, advances in treatment and enhancements in bladder cancer diagnosis. Additionally, new therapies and more information about this disease have facilitated a change in this field, which allows health practitioners to have a better understanding of the ailment, thus saving more lives. However, bladder cancer is still among the most common cancers in the Unites States and also the most expensive, with regard to cancer care. The majority of diagnosed bladder…

Continue Reading

ThursdayJun 10, 2021 10:46 am

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Present at H.C. Wainwright’s Upcoming Virtual Psychedelics Conference

Tryp Therapeutics’ Chairman and CEO Greg McKee will present at the virtual Psychedelics in Psychiatry and Beyond Conference planned for Thursday, June 17, 2021 As part of his presentation, McKee will discuss Tryp’s business and its pipeline, which includes its proprietary psilocybin-centered drug development program Tryp will present alongside other pharmaceutical companies leading research in psychedelic-assisted therapeutics Psychedelics have increasingly drawn the attention of different players and companies thanks to the research-driven revelations regarding their utility in treating a wide range of neuropsychiatric diseases.  As a pharmaceutical company that has been furthering such research – specifically on psilocybin, a psychedelic…

Continue Reading

ThursdayJun 10, 2021 10:06 am

United Medical Equipment Business Solutions Network Inc. May Offer Response to US Prescription Drugs Price Crisis; Provides GoodRx Functionality within its Medication Management App

Americans pay more for prescription drugs than any other nation in the world; prices keep increasing Patients pay about 14% of prescription drug costs out of pockets; around 20% report not being able to complete a prescribed course of medicine due to costs UME's committed to providing consumers better access to the healthcare they need; its Medication Management App features GoodRx in-built functionality enabling them to view discount prices and coupons United Medical Equipment Business Solutions Network ("UME") has developed the Medication Management App with twelve different functionalities within the convenience of one application, with the newest addition of GoodRX…

Continue Reading

ThursdayJun 10, 2021 9:53 am

Brain Scientific Inc. (BRSF) Poised to Offer Brain Monitoring Solution as Research Shows Neurological Findings in COVID-19 Long-Haulers

Most extensive research to date reports significant neurological problems in patients who suffered from so-called long-haul COVID-19 Neurological issues range from mild to more severe such as cognitive impairment, which affects around 20% of these patients BRSF appears poised to be part of the solution as long-haulers need monitoring so that doctors can assess if they have neurological disorders The neurological and psychiatric aftermath of COVID-19 has been reported, but adequately assessing the effects of the disease on brain health still remains a challenge. A new preprint analysis, representing one of the most extensive studies of neuropsychiatric symptoms among COVID-19…

Continue Reading

ThursdayJun 10, 2021 9:00 am

RYAH Group Inc. (CSE: RYAH) Reports on the Medical Benefits of the “Munchies”

Reported on the therapeutic benefit of munchies for nausea and vomiting Recorded over 14,500 sessions from patients seeking relief from nausea Munchies are a medical benefit for those going through chemotherapy or diagnosed with cachexia, also known as a wasting disorder RYAH Group (CSE: RYAH), the leading data technology company in plant-based medicine, collects data through its IoT dose-measuring devices and AI analytics. Recently the company reported on The Therapeutic Benefit of the Munchies for Nausea and Vomiting. The full article can be found at https://ibn.fm/mgkad. RYAH is uniquely positioned to collect essential data that can lead to more personalized…

Continue Reading

WednesdayJun 09, 2021 12:48 pm

Digitization May Be the Future of the Healthcare Sector

A report that was recently released highlights that medical service leaders from various countries believe that being prepared for crises that may arise in the future and strengthening resilience should be a top priority. The senior healthcare leaders from countries such as India, Germany and the United States, were questioned about their digitization plans. Their responses were recorded through surveys. The coronavirus pandemic has affected many industries and economies, with more nations adopting telemedicine in their healthcare sectors and using video and phone appointments to provide consultations, as opposed to in-person visits. IDC, an industry analyst firm, forecasts that in…

Continue Reading

WednesdayJun 09, 2021 9:15 am

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Files International Patent to Protect Potential Patient Coverage in 153 Countries

Cybin submits first-ever Patent Cooperation Treaty (“PCT”) filing By filing a single PCT application, the company simultaneously seeks protection for its proprietary drug treatments in a large number of countries Cybin filed the PCT application to provide broad international patent protection of key intellectual property Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, continues to focus on its goal to improve the lives of those suffering from mental illness by changing the expectation of treatment. As part of that mission, the company has filed an international patent application that would provide the potential to obtain patent…

Continue Reading

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050